Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Palleon Pharmaceuticals Inc. is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution suggests that the company's pharmaceutical research spans different specialized areas within the USPTO, reflecting a broader technological scope than a more centralized portfolio.
LAURA B GODDARD is the busiest examiner for the company, managing 1 pending office action. Since there are 2 pending office actions in total, this examiner handles 1 of them. The involvement of 2 distinct art units suggests that the company's biotechnology innovations may have diverse applications requiring different examination expertise. Practitioners must manage the 2 distinct examiners across 2 distinct art units, which may result in varying prosecution timelines and requirements for each of the pending matters currently under review.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GODDARD, LAURA B | 1 | 50.9% | +13.5% |
| BORGEEST, CHRISTINA M | 1 | 55.6% | +21.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17624121 | RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS, AND METHODS OF USING THE SAME | BORGEEST, CHRISTINA M | 51d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17624121 | RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS, AND METHODS OF USING THE SAME | BORGEEST, CHRISTINA M | 51d overdue |
| 18003234 | RECOMBINANT SIALIDASES WITH REDUCED PROTEASE SENSITIVITY, SIALIDASE FUSION PROTEINS, AND METHODS OF USING THE SAME | GODDARD, LAURA B | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18003234 | RECOMBINANT SIALIDASES WITH REDUCED PROTEASE SENSITIVITY, SIALIDASE FUSION PROTEINS, AND METHODS OF USING THE SAME | GODDARD, LAURA B | 1642 | §102§112DP | Non-Final OA | — | Pending | Dec 23, 2022 |
| 17624121 | RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS, AND METHODS OF USING THE SAME | BORGEEST, CHRISTINA M | 1675 | §102§112 | Non-Final OA | 51d overdue | Pending | Dec 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial